Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 82

Sort by

Sort Order Select

Journal Articles

Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma

Blood (2025) 145 (1): 85–97.

https://doi.org/10.1182/blood.2024025945

Published: 2025

Includes: Supplemental data

Journal Articles

Comparative Safety and Efficacy of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel CAR T-Cell Therapies in Relapsed or Refractory Multiple Myeloma

Doris K. Hansen, Lauren C. Peres, Danai Dima, Alicia Richards, Leyla O. Shune, Aimaz Afrough, Shonali Midha, Binod Dhakal, Mehmet H. Kocoglu, Shebli Atrash, Chris Ferreri, Omar Castaneda, James A Davis, Evguenia Ouchveridze, Joseph P. McGuirk, Charlotte B Wagner, Radhika Bansal, Patrick Costello, Kinaya Smith, Alex Lieberman-Cribbin, Gabriel De Avila, Sneha Purvey, Hitomi Hosoya, Lekha Mikkilineni, Laura B. Oswald, Gurbakhash Kaur, Oren Pasvolsky, Mahmoud R. Gaballa, Megan M Herr, Peter A. Forsberg, Murali Janakiram, Myo Htut, Sireesha Asoori, Nilesh Kalariya, Hamza Hashmi, Ran Reshef, Douglas W Sborov, Omar Nadeem, Faiz Anwer, Jack Khouri, Shahzad Raza, Djordje Atanackovic, Melissa Alsina, Ciara Louise Freeman, Frederick L. Locke, Peter M. Voorhees, Larry D Anderson, Jr., Shambavi Richard, Thomas Martin, Yi Lin, Krina K. Patel, Surbhi Sidana

Blood (2024) 144 (Supplement 1): 936.

https://doi.org/10.1182/blood-2024-194390

Published: 2024

Journal Articles

Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Analyses of Minimal Residual Disease (MRD) Negativity Dynamics in the Phase 3 Imroz Study

Blood (2024) 144 (Supplement 1): 770.

https://doi.org/10.1182/blood-2024-203818

Published: 2024

Journal Articles

Efficacy of Stem Cell Boost (SCB) for Chimeric Antigen Receptor T Cell (CAR-T)-Related Hematologic Toxicity in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)- a Multi-Center Real World Experience

Blood (2024) 144 (Supplement 1): 4712.

https://doi.org/10.1182/blood-2024-204257

Published: 2024

Journal Articles

Racial and Ethnic Differences in Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel or Ciltacabtagene Autoleucel

Lauren C. Peres, Alicia Richards, Surbhi Sidana, Laura B. Oswald, Danai Dima, Aimaz Afrough, Leyla O. Shune, Shonali Midha, Omar Castaneda, Christopher Ferreri, James A Davis, Oren Pasvolsky, Christen M. Dillard, Megan M Herr, Mehmet H. Kocoglu, Shebli Atrash, Brandon Blue, Evguenia Ouchveridze, Joseph P. McGuirk, Charlotte B Wagner, Radhika Bansal, Patrick Costello, Kinaya Smith, Alex Lieberman-Cribbin, Gabriel De Avila, Sneha Purvey, Hitomi Hosoya, Lekha Mikkilineni, Gurbakhash Kaur, Mahmoud R. Gaballa, Peter A. Forsberg, Ciara Louise Freeman, Murali Janakiram, Myo Htut, Sireesha Asoori, Nilesh Kalariya, Djordje Atanackovic, Binod Dhakal, Jack Khouri, Shahzad Raza, Ran Reshef, Melissa Alsina, Frederick L. Locke, Omar Nadeem, Faiz Anwer, Larry D Anderson, Jr., Shambavi Richard, Yi Lin, Thomas Martin, Peter M. Voorhees, Krina K. Patel, Doris K. Hansen, Douglas W Sborov

Blood (2024) 144 (Supplement 1): 3785.

https://doi.org/10.1182/blood-2024-210078

Published: 2024

Journal Articles

Single-Cell Analysis Reveals Depletion of Antigen-Presenting Cell (APC) and IFN-Stimulated CD4 T Cell Populations in High-Risk Newly Diagnosed Multiple Myeloma Patients

Blood (2024) 144 (Supplement 1): 4654.

https://doi.org/10.1182/blood-2024-208308

Published: 2024

Journal Articles

Feasibility and Implementation of the ASH Research Collaborative's COVID-19 Outcomes in Myeloma and the Impact of Vaccines (COSMIC): A Decentralized, Real-World Evidence Study for Patients with Multiple Myeloma to Monitor Outcomes Related to COVID-19 Vaccines and Infections

Blood (2024) 144 (Supplement 1): 2393.

https://doi.org/10.1182/blood-2024-203892

Published: 2024

Journal Articles

Health-Related Quality of Life (HRQoL) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplantation and Treated with Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Vs. Vrd Alone: Results from the Imroz Study

Blood (2024) 144 (Supplement 1): 3352.

https://doi.org/10.1182/blood-2024-207087

Published: 2024

Journal Articles

Development of the ASH Research Collaborative Multiple Myeloma Program: A Multicenter, Real-World Evidence Generation Network

Blood (2024) 144 (Supplement 1): 3792.5.

https://doi.org/10.1182/blood-2024-210957

Published: 2024

Journal Articles

Initial Results from the ASH Research Collaborative's COVID-19 Outcomes in Myeloma and the Impact of Vaccines (COSMIC): A Decentralized, Real-World Evidence Study for Patients with Multiple Myeloma to Monitor Outcomes Related to COVID-19 Vaccines and Infections

Blood (2024) 144 (Supplement 1): 1972.

https://doi.org/10.1182/blood-2024-210377

Published: 2024

Journal Articles

Outcomes of Frailty Subgroups Treated with Teclistamab in the Real-World: An International Myeloma Foundation Study Database Analysis

Hira Mian, Carlyn Rose Tan, Sireesha Asoori, Rakesh Popat, Nadine Abdallah, Saurabh Chhabra, Ricardo D. Parrondo, Gregory R Pond, Thomas Martin, Brian G.M. Durie, Yi Lin

Blood (2024) 144 (Supplement 1): 704.

https://doi.org/10.1182/blood-2024-200877

Published: 2024

Journal Articles

Delayed Neurotoxicity after CAR-T in Multiple Myeloma: Results from a Global IMWG Registry

Blood (2024) 144 (Supplement 1): 4758.

https://doi.org/10.1182/blood-2024-201783

Published: 2024

Journal Articles

Alternative Lymphodepletion Strategies Lead to Similar Response Rates and Toxicities in Standard-of-Care BCMA-Directed CAR-T Therapy in Relapsed Refractory Multiple Myeloma

Blood (2023) 142 (Supplement 1): 3499.

https://doi.org/10.1182/blood-2023-187565

Published: 2023

Journal Articles

Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B-Cell Maturation Antigen (BCMA) × CD3 T-Cell Engager (TCE), Administered Subcutaneously (SC) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 First-in-Human Clinical Study

Blood (2023) 142 (Supplement 1): 2011.

https://doi.org/10.1182/blood-2023-180013

Published: 2023

Journal Articles

The Impact of Isatuximab Regimens on Hypogammaglobulinemia Occurrence, Recovery, and Associated Infections in Patients with Relapsed/Refractory Multiple Myeloma

Cesar Rodriguez, Aurore Perrot, Paul G. Richardson, Thierry Facon, Ivan Spicka, Albert Oriol, Kenshi Suzuki, Edvan Crusoe, Ajai Chari, Nicole Armstrong, Christina Tekle, Marie-Laure Risse, Thomas Martin, Philippe Moreau

Blood (2023) 142 (Supplement 1): 1980.

https://doi.org/10.1182/blood-2023-179925

Published: 2023

Journal Articles

Ablation of Cullin-5 in Primary Human T Cells Improves Tumor Killing and Persistence in BCMA-Targeting CAR-T Cells in a Multiple Myeloma Model

Stefanie Bachl, Alexis Talbot, Carter Ching, Nupura Kale, Zhongmei Li, Morgan Diolaiti, Amy Peixin Chen, Joseph Muldoon, Chang Liu, Thomas Martin, Justin Eyquem, Julia Carnevale

Blood (2023) 142 (Supplement 1): 99.

https://doi.org/10.1182/blood-2023-182565

Published: 2023

Journal Articles

Real-World Evaluation of Teclistamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM)

Sireesha Asoori, Rakesh Popat, Joaquín Martínez-Lopez, Efstathios Kastritis, Larissa Brunaldi, Radhika Bansal, Andre De Menezes Silva Corraes, Kwee Yong, Catriona Mactier, Magdalena Corona, Adolfo Jesús Sáez Marín, Despina Fotiou, Meletios Athanasios Dimopoulos, Saurabh Chhabra, Sikander Ailawadhi, Ricardo Parrondo, Thomas Martin, Brian GM Durie, Yi Lin

Blood (2023) 142 (Supplement 1): 3347.

https://doi.org/10.1182/blood-2023-190793

Published: 2023

Journal Articles

Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents

Blood (2023) 141 (3): 219–230.

https://doi.org/10.1182/blood.2022015526

Published: 2023

Includes: Supplemental data

Journal Articles

Significance of the Pee-Value: Relevance of Urine Studies for Patients with Myeloma Undergoing Transplantation

Kelsey H. Natsuhara, Chiung-Yu Huang, Jennifer Knoche, Shagun Arora, Alfred Chung, Thomas Martin, Jeffrey L. Wolf, Sandy W. Wong, Nina Shah, Rahul Banerjee

Blood (2022) 140 (Supplement 1): 7910–7912.

https://doi.org/10.1182/blood-2022-155906

Published: 2022

Journal Articles

Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: Ikema Subgroup Analysis By Number of Prior Lines of Treatment

Marcelo Capra, Thomas Martin, Philippe Moreau, Gracia Martinez, Albert Oriol, Youngil Koh, Hang Quach, Kwee Yong, Andreea Rawlings, Christina Tekle, Sandrine Macé, Marie-Laure Risse, Ivan Spicka

Blood (2022) 140 (Supplement 1): 7138–7140.

https://doi.org/10.1182/blood-2022-162731

Published: 2022

NARROW

Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma

Comparative Safety and Efficacy of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel CAR T-Cell Therapies in Relapsed or Refractory Multiple Myeloma

Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Analyses of Minimal Residual Disease (MRD) Negativity Dynamics in the Phase 3 Imroz Study

Efficacy of Stem Cell Boost (SCB) for Chimeric Antigen Receptor T Cell (CAR-T)-Related Hematologic Toxicity in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)- a Multi-Center Real World Experience

Racial and Ethnic Differences in Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel or Ciltacabtagene Autoleucel

Single-Cell Analysis Reveals Depletion of Antigen-Presenting Cell (APC) and IFN-Stimulated CD4 T Cell Populations in High-Risk Newly Diagnosed Multiple Myeloma Patients

Feasibility and Implementation of the ASH Research Collaborative's COVID-19 Outcomes in Myeloma and the Impact of Vaccines (COSMIC): A Decentralized, Real-World Evidence Study for Patients with Multiple Myeloma to Monitor Outcomes Related to COVID-19 Vaccines and Infections

Health-Related Quality of Life (HRQoL) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplantation and Treated with Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Vs. Vrd Alone: Results from the Imroz Study

Development of the ASH Research Collaborative Multiple Myeloma Program: A Multicenter, Real-World Evidence Generation Network

Initial Results from the ASH Research Collaborative's COVID-19 Outcomes in Myeloma and the Impact of Vaccines (COSMIC): A Decentralized, Real-World Evidence Study for Patients with Multiple Myeloma to Monitor Outcomes Related to COVID-19 Vaccines and Infections

Outcomes of Frailty Subgroups Treated with Teclistamab in the Real-World: An International Myeloma Foundation Study Database Analysis

Delayed Neurotoxicity after CAR-T in Multiple Myeloma: Results from a Global IMWG Registry

Alternative Lymphodepletion Strategies Lead to Similar Response Rates and Toxicities in Standard-of-Care BCMA-Directed CAR-T Therapy in Relapsed Refractory Multiple Myeloma

Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B-Cell Maturation Antigen (BCMA) × CD3 T-Cell Engager (TCE), Administered Subcutaneously (SC) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 First-in-Human Clinical Study

The Impact of Isatuximab Regimens on Hypogammaglobulinemia Occurrence, Recovery, and Associated Infections in Patients with Relapsed/Refractory Multiple Myeloma

Ablation of Cullin-5 in Primary Human T Cells Improves Tumor Killing and Persistence in BCMA-Targeting CAR-T Cells in a Multiple Myeloma Model

Real-World Evaluation of Teclistamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM)

Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents

Significance of the Pee-Value: Relevance of Urine Studies for Patients with Myeloma Undergoing Transplantation

Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: Ikema Subgroup Analysis By Number of Prior Lines of Treatment

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only